{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:31:35Z","timestamp":1790451095790,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1016\/j.beha.2005.01.008","type":"journal-article","created":{"date-parts":[[2005,7,17]],"date-time":"2005-07-17T12:33:11Z","timestamp":1121603591000},"page":"553-568","source":"Crossref","is-referenced-by-count":60,"title":["Multiple myeloma: clinical features and indications for therapy"],"prefix":"10.1016","volume":"18","author":[{"given":"Angela","family":"Dispenzieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.beha.2005.01.008_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"Cancer statistics, 2004","volume":"54","author":"Jemal","year":"2004","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.beha.2005.01.008_bib2","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/jnci\/93.11.824","article-title":"Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends","volume":"93","author":"Howe","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.beha.2005.01.008_bib3","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2000.02318.x","article-title":"Multiple myeloma: an odyssey of discovery","volume":"111","author":"Kyle","year":"2000","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2005.01.008_bib4","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group","year":"2003","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2005.01.008_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.beha.2005.01.008_bib6","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/0277-5379(91)90020-E","article-title":"Changing clinical presentation of multiple myeloma","volume":"27","author":"Riccardi","year":"1991","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.beha.2005.01.008_bib7","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0301-472X(99)00105-8","article-title":"Relation between S-phase fraction of myeloma cells and anemia in patients with multiple myeloma","volume":"27","author":"Fossa","year":"1999","journal-title":"Exp Hematol"},{"issue":"4","key":"10.1016\/j.beha.2005.01.008_bib8","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1182\/blood.V99.4.1305","article-title":"Negative regulation of erythroblast maturation by Fas-L(+)\/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma","volume":"99","author":"Silvestris","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2005.01.008_bib9","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1182\/blood.V97.9.2900","article-title":"Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma","volume":"97","author":"Drayson","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2005.01.008_bib10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2141.1983.tb02851.x","article-title":"Prognostic value of bone marrow plasma cell infiltration in stage I multiple myeloma","volume":"55","author":"Cavo","year":"1983","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2005.01.008_bib11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ajh.10003","article-title":"Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation","volume":"68","author":"Rajkumar","year":"2001","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.beha.2005.01.008_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0753-3322(96)85095-5","article-title":"Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model","volume":"50","author":"Pasqualetti","year":"1996","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.beha.2005.01.008_bib13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.V65.2.305.305","article-title":"Multiple myeloma: significance of plasmablastic subtype in morphological classification","volume":"65","author":"Greipp","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.01.008_bib14","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1182\/blood.V3.9.987.987","article-title":"Bone marrow on sternal aspiration in multiple myeloma","volume":"3","author":"Bayrd","year":"1948","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2005.01.008_bib15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.1994.tb08304.x","article-title":"Bone marrow angiogenesis and progression in multiple myeloma","volume":"87","author":"Vacca","year":"1994","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2005.01.008_bib16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.leu.2401336","article-title":"Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma","volume":"13","author":"Rajkumar","year":"1999","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2005.01.008_bib17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1365-2141.1997.4503260.x","article-title":"Bone marrow fibrosis and disease activity in multiple myeloma monitored by the aminoterminal propeptide of procollagen III in serum","volume":"99","author":"Abildgaard","year":"1997","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2005.01.008_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ajcp\/89.1.63","article-title":"Marrow fibrosis and multiple myeloma","volume":"89","author":"Krzyzaniak","year":"1988","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.beha.2005.01.008_bib19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0950-3536(05)80257-4","article-title":"Immunophenotype and DNA cell content in multiple myeloma","volume":"8","author":"San Miguel","year":"1995","journal-title":"Baillieres Clin Haematol"},{"issue":"12","key":"10.1016\/j.beha.2005.01.008_bib20","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1038\/sj.leu.2401211","article-title":"The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma","volume":"12","author":"Pellat-Deceunynck","year":"1998","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2005.01.008_bib21","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2141.1991.tb08050.x","article-title":"Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells","volume":"79","author":"Van Riet","year":"1991","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2005.01.008_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2141.1992.tb08236.x","article-title":"Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells","volume":"81","author":"Barker","year":"1992","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2005.01.008_bib23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2141.1996.tb08993.x","article-title":"Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells","volume":"95","author":"Ocqueteau","year":"1996","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2005.01.008_bib24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood.V62.1.166.166","article-title":"Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma","volume":"62","author":"Greipp","year":"1983","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2005.01.008_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2141.1999.01136.x","article-title":"Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders","volume":"104","author":"Witzig","year":"1999","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2005.01.008_bib26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/hon.2900100209","article-title":"The biological and clinical significance of the KI-67 growth fraction in multiple myeloma","volume":"10","author":"Drach","year":"1992","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1016\/j.beha.2005.01.008_bib27","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1182\/blood.V85.2.448.448","article-title":"A new staging system for multiple myeloma based on the number of S-phase plasma cells","volume":"85","author":"San Miguel","year":"1995","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2005.01.008_bib28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/(SICI)1096-8652(199712)56:4<288::AID-AJH16>3.0.CO;2-5","article-title":"Multiple myeloma associated with diffuse osteosclerotic bone lesions: a clinical entity distinct from osteosclerotic myeloma (POEMS syndrome)","volume":"56","author":"Lacy","year":"1997","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.beha.2005.01.008_bib29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.0954-6820.1980.tb01196.x","article-title":"Skeletal scintigraphy with technetium diphosphonate in multiple myeloma\u2014a comparison with skeletal x-ray","volume":"208","author":"Lindstrom","year":"1980","journal-title":"Acta Med Scand"},{"issue":"2","key":"10.1016\/j.beha.2005.01.008_bib30","first-page":"119","article-title":"Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy","volume":"84","author":"Catalano","year":"1999","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.beha.2005.01.008_bib31","first-page":"171","article-title":"Comparison of MRI and computed tomography in the various stages of plasma cell disorders: correlations with biological and histological findings. Myelome\u2013Midi\u2013Pyrenees group","volume":"14","author":"Laroche","year":"1996","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.beha.2005.01.008_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2141.1999.01529.x","article-title":"Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey","volume":"106","author":"Lecouvet","year":"1999","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2005.01.008_bib33","first-page":"837","article-title":"Magnetic resonance imaging of the spine in plasma cell dyscrasias. A review","volume":"63","author":"Pertuiset","year":"1996","journal-title":"Rev Rhum Engl Ed"},{"issue":"3","key":"10.1016\/j.beha.2005.01.008_bib34","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.beha.2005.01.008_bib35","first-page":"1457","article-title":"Whole-body (18)F-FDG PET identifies high-risk myeloma","volume":"43","author":"Durie","year":"2002","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.beha.2005.01.008_bib36","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00259-001-0711-3","article-title":"Initial results in the assessment of multiple myeloma using (18)F-FDG PET","volume":"29","author":"Schirrmeister","year":"2002","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.beha.2005.01.008_bib37","doi-asserted-by":"crossref","unstructured":"Analysis and management of renal failure in fourth MRC myelomatosis trial. MRC working party on leukaemia in adults. Br Med J (Clin Res Ed) 1984; 288(6428): 1411\u20131416.","DOI":"10.1136\/bmj.288.6428.1411"},{"issue":"5","key":"10.1016\/j.beha.2005.01.008_bib38","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00005792-198009000-00005","article-title":"Multiple myeloma: a clinicopathologic study of 62 consecutively autopsied cases","volume":"59","author":"Kapadia","year":"1980","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.beha.2005.01.008_bib39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2003-10-3400","article-title":"Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma","volume":"104","author":"Ma","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2005.01.008_bib40","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0002-9343(81)90303-X","article-title":"Influence of treatment and response status on infection risk in multiple myeloma","volume":"71","author":"Perri","year":"1981","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.beha.2005.01.008_bib41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7326\/0003-4819-96-1-47","article-title":"Biphasic pattern of bacterial infection in multiple myeloma","volume":"96","author":"Savage","year":"1982","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.beha.2005.01.008_bib42","first-page":"125","article-title":"Hemostatic abnormalities associated with dysproteinemias","volume":"10","author":"Lackner","year":"1973","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.beha.2005.01.008_bib43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1365-2141.1997.d01-2145.x","article-title":"Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder","volume":"97","author":"Colwell","year":"1997","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2005.01.008_bib44","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/152581601753193869","article-title":"Bleeding diathesis in multiple myeloma","volume":"10","author":"Saif","year":"2001","journal-title":"J Hematother Stem Cell Res"},{"issue":"3","key":"10.1016\/j.beha.2005.01.008_bib45","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1172\/JCI109712","article-title":"Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder","volume":"65","author":"Khoory","year":"1980","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.beha.2005.01.008_bib46","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-2003-40965","article-title":"The blood coagulation mechanism in multiple myeloma","volume":"29","author":"Zangari","year":"2003","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"10.1016\/j.beha.2005.01.008_bib47","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0889-8588(05)70125-8","article-title":"Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia","volume":"13","author":"Blade","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"10.1016\/j.beha.2005.01.008_bib48","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1200\/JCO.1994.12.11.2398","article-title":"Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases","volume":"12","author":"Blade","year":"1994","journal-title":"J Clin Oncol"},{"issue":"5\u20136","key":"10.1016\/j.beha.2005.01.008_bib49","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3109\/10428199909058419","article-title":"IgE multiple myeloma","volume":"32","author":"Macro","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.beha.2005.01.008_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ajh.2830480201","article-title":"Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. The Groupe d'Etudes et de Recherche sur le Myelome (GERM)","volume":"48","author":"Facon","year":"1995","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.beha.2005.01.008_bib51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan\u2013prednisone therapy for asymptomatic multiple myeloma stage I\u2014a randomized study. Myeloma group of western Sweden","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2005.01.008_bib52","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0959-8049(94)00452-B","article-title":"A comparison of polychemotherapy and melphalan\/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German myeloma treatment group","volume":"2","author":"Peest","year":"1995","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.beha.2005.01.008_bib53","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative group of study and treatment of multiple myeloma","volume":"82","author":"Riccardi","year":"2000","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.beha.2005.01.008_bib54","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1046\/j.1365-2141.1997.1122939.x","article-title":"Prognostic features of asymptomatic multiple myeloma","volume":"97","author":"Weber","year":"1997","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2005.01.008_bib55","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2141.1995.tb08378.x","article-title":"Detection of monoclonal plasma cells in the peripheral blood stem cell harvests of patients with multiple myeloma","volume":"89","author":"Witzig","year":"1995","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.beha.2005.01.008_bib56","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1080\/1042819031000099715","article-title":"Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial","volume":"44","author":"Musto","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.beha.2005.01.008_bib57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5414\/CNP61063","article-title":"Pamidronate-induced nephrotoxic tubular necrosis\u2014a case report","volume":"61","author":"Smetana","year":"2004","journal-title":"Clin Nephrol"},{"issue":"5","key":"10.1016\/j.beha.2005.01.008_bib58","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"issue":"4","key":"10.1016\/j.beha.2005.01.008_bib59","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.leu.2402866","article-title":"Thalidomide as initial therapy for early-stage myeloma","volume":"17","author":"Rajkumar","year":"2003","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.beha.2005.01.008_bib60","first-page":"190a","article-title":"A new international staging system (ISS) for multiple myeloma (MM) from the international myeloma working group","volume":"102","author":"Greipp","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2005.01.008_bib61","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2005.01.008_bib62","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0272-6386(12)80314-3","article-title":"Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease","volume":"20","author":"Heilman","year":"1992","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1016\/j.beha.2005.01.008_bib63","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood-2002-07-2299","article-title":"POEMS syndrome: definitions and long-term outcome","volume":"101","author":"Dispenzieri","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2005.01.008_bib64","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00005792-198007000-00006","article-title":"Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature","volume":"59","author":"Bardwick","year":"1980","journal-title":"Medicine (Baltimore)"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692605000071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692605000071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T22:37:55Z","timestamp":1706395075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692605000071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S1521692605000071"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2005.01.008","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}